Humanized Anti-TAG 72 CC49 for Diagnosis and Therapy of Human Carcinomas
Description of Invention:
Tumor associated glycoprotein (TAG-72) is expressed on the cells of a majority of human carcinomas, including colorectal, gastric, pancreatic, breast, lung, and ovarian. The murine monoclonal antibody (mAb) CC49 specifically recognizes TAG-72 and has a higher affinity for TAG-72 than its predecessor, B72.3.
The present invention discloses new humanized variants of CC49 that have a higher binding affinity to TAG-72 than previous humanized variants. Identified as HuCC49V15 and HuCC49V14, these variants also retain low immunogenicity of variable regions using sera of patients vaccinated with murine CC49.
These variants have potential benefits for use in the detection and/or treatment of a range of human carcinomas. Certain fields of use may not be available. Please contact OTT for information regarding the availability of specific fields of use.
Patent Status:
DHHS Reference No. E-013-2002/0 --
U.S. Provisional Application No. 60/393,077 filed 28 Jun 2002
PCT Application No. PCT/US03/20367 filed 26 Jun 2003, which published as WO 2004/003155 on 08 Jan 2004
U.S. Patent Application No. 10/519,580 filed 11 Jul 2005
Portfolios: Cancer
Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: Michelle A. Booden Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)451-7337
Email: boodenm@mail.nih.gov
Fax: (301) 402-0220
